Höglinger Günter, Trenkwalder Claudia
Department of Neurology With Friedrich Baur Institute, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Marchioninistr. 15, Munich, 81377, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Neurol Res Pract. 2024 Jun 6;6(1):30. doi: 10.1186/s42466-024-00325-4.
The aim of this German national guideline is to optimize the clinical care of patients with Parkinson's disease (PD) in terms of diagnostics, drug and surgical treatment and care. This guidance was prepared for the German Society of Neurology (DGN) in collaboration with the Austrian Society of Neurology (ÖGN) and the Swiss Neurological Society (SNG) for German-speaking countries. The guidelines for the diagnosis and treatment of PD have been revised by a national expert group and the guideline commission of the DGN at S2k level. The main objective of these guidelines is to optimize the clinical care of PD patients regarding diagnosis, including early detection, technical diagnostic examinations, and pharmacological as well as invasive treatment options.
The updated PD diagnosis and treatment guidelines are emphasizing optimized clinical care. Key revisions include preferring the name "Parkinson's disease" over previous terms and adopting International Parkinson and Movement Disorder Society (MDS) diagnostic criteria. Recommendations cover genetic and imaging diagnostics, initial pharmacotherapy considering efficacy and patient factors, and tailored pharmacological combinations for complications. Guidelines extend to managing cognitive, affective, psychotic, and autonomic symptoms, along with non-oral therapies like pump therapy and deep brain stimulation. Special situations like akinetic crisis, driving ability, and care concepts are addressed, ensuring comprehensive management for PD patients at various stages and conditions.
This guidance reflects the state of the art at the beginning of 2024.
本德国国家指南的目的是在诊断、药物和手术治疗及护理方面优化帕金森病(PD)患者的临床护理。本指南是德国神经病学学会(DGN)与奥地利神经病学学会(ÖGN)和瑞士神经病学学会(SNG)合作,为德语国家制定的。PD的诊断和治疗指南已由一个国家专家组和DGN的指南委员会在S2k级别进行了修订。这些指南的主要目标是在诊断方面优化PD患者的临床护理,包括早期检测、技术诊断检查以及药物和侵入性治疗选择。
更新后的PD诊断和治疗指南强调优化临床护理。关键修订包括优先使用“帕金森病”这一名称而非之前的术语,并采用国际帕金森和运动障碍协会(MDS)的诊断标准。建议涵盖基因和影像诊断、考虑疗效和患者因素的初始药物治疗,以及针对并发症的定制药物组合。指南还扩展到管理认知、情感、精神和自主神经症状,以及泵治疗和深部脑刺激等非口服治疗。解决了如运动不能危象、驾驶能力和护理概念等特殊情况,确保对不同阶段和状况的PD患者进行全面管理。
本指南反映了2024年初的最新技术水平。